PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Boulding sold 2,812 shares of the firm’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $61.88, for a total transaction of $174,006.56. Following the completion of the sale, the vice president owned 105,272 shares of the company’s stock, valued at $6,514,231.36. The trade was a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mark Elliott Boulding also recently made the following trade(s):
- On Friday, October 9th, Mark Boulding sold 192 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.26, for a total transaction of $12,337.92.
- On Monday, October 5th, Mark Boulding sold 1,638 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.03, for a total transaction of $104,881.14.
- On Tuesday, October 6th, Mark Boulding sold 435 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60.
PTC Therapeutics Price Performance
PTCT stock opened at $58.33 on Friday. The stock has a market capitalization of $4.87 billion, a PE ratio of -41.66, a price-to-earnings-growth ratio of 4.42 and a beta of 0.52. The company’s 50-day moving average is $63.45 and its 200-day moving average is $69.96. PTC Therapeutics, Inc. has a 1 year low of $58.15 and a 1 year high of $90.87.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the consensus estimate of $0.14 by ($0.76). The firm had revenue of $357.81 million during the quarter, compared to the consensus estimate of $306.43 million. During the same period in the previous year, the company posted $0.20 EPS. PTC Therapeutics’s revenue for the quarter was up 69.6% compared to the same quarter last year. On average, analysts anticipate that PTC Therapeutics, Inc. will post 0.49 earnings per share for the current fiscal year.
PTC Therapeutics declared that its Board of Directors has initiated a stock repurchase program on Tuesday, November 3rd that permits the company to buy back $500 million in outstanding shares. This repurchase authorization permits the biopharmaceutical company to buy up to 9.8% of its shares through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its stock is undervalued.
Institutional Investors Weigh In On PTC Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in PTCT. EverSource Wealth Advisors LLC increased its holdings in PTC Therapeutics by 16.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 151 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its stake in shares of PTC Therapeutics by 1.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 13,730 shares of the biopharmaceutical company’s stock worth $1,120,000 after purchasing an additional 237 shares during the last quarter. Allworth Financial LP raised its stake in shares of PTC Therapeutics by 29.0% in the third quarter. Allworth Financial LP now owns 1,055 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 237 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of PTC Therapeutics by 8.5% in the first quarter. PNC Financial Services Group Inc. now owns 3,128 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 244 shares in the last quarter. Finally, State of Wyoming lifted its holdings in shares of PTC Therapeutics by 15.3% in the third quarter. State of Wyoming now owns 1,962 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 260 shares in the last quarter.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on PTCT shares. Zacks Research downgraded PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. TD Cowen upped their target price on PTC Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Cantor Fitzgerald increased their target price on PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a report on Tuesday, September 22nd. Wall Street Zen downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. Finally, Leerink Partners initiated coverage on shares of PTC Therapeutics in a research report on Monday, September 14th. They issued an “outperform” rating and a $98.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, PTC Therapeutics has an average rating of “Moderate Buy” and an average price target of $99.23.
View Our Latest Report on PTCT
PTC Therapeutics Company Profile
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
Recommended Stories
- Five stocks we like better than PTC Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
